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With the advent of effective HAART and subsequent
improved survival and also with ongoing HIV transmis-
sion including amongst older persons, the HIV positive
population accessing care is ageing and a significant
proportion of patients (up to 25% in some cohorts) are
now aged over 50.
Older age has an effect on both HIV natural history
and response to HAART. Older persons in the pre-
HAART era progressed more rapidly to AIDS or death
after seroconversion and AIDS diagnoses occurred at
higher CD4 counts. Virological response to HAART is
typically greater in older patients, likely mediated by
greater levels of adherence, although immunological
responses appear blunted. Some HAART toxicities
occur at a higher frequency on older patients, although
tolerance of adverse effects may be greater.
Additionally, it is increasingly suggested that HIV may
result in accelerated ageing. This is thought to result
from a combination of lifestyle factors, drug toxicities,
and chronic inflammation/immune activation which
persists even in the setting of virological suppression.
Morbidities that were not historically considered to be
HIV-related (e.g. cardiovascular disease, osteopaenia,
“non-AIDS” malignancies) are now considered to be
related to both ongoing HIV replication and chronic
immune activation, and all are associated with increas-
ing age.
It is therefore likely that HIV treatment recommenda-
tions (such as when to start HAART and what to start
with) may need to be adapted for the older patient.
Furthermore, older patients with HIV are likely to
increasingly experience multiple co-morbidites which
will require complex management and significant chal-
lenges to healthcare delivery.
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